Jian-Qiang Wu1, Mei-Ping Lu1, Ann M Reed2. 1. Department of Rheumatology Immunology and Allergy, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310052, China. 2. Department of Pediatrics, Division of Pediatric Rheumatology, Duke University School of Medicine, Durham, 27710, USA. ann.reed@duke.edu.
Abstract
BACKGROUND: Juvenile dermatomyositis (JDM) is a chronic autoimmune disease characteristic by inflammation of small vessels within the skin, muscle and vital organs. But the clinical features and treatment of JDM have not been fully clarified. DATA SOURCES: Databases underwent through PubMed for articles about the clinical features, myositis-specific antibodies of JDM and its treatment, and we selected publications written in English which were relevant to the topic of this review. RESULTS: Clinical features and myositis-specific antibodies may predict the severity and prognosis of disease. Although the mortality rate has been lower with traditional treatments, such as corticosteroid, intravenous immunoglobulin, and disease-modifying anti-rheumatic drugs such as methotrexate, their usages are variable. Novel biological therapies seem to be effective for refractory JDM patients, but more clinical trials are necessary. CONCLUSIONS: JDM is a sever disease of childhood. We need to better understand recent advances of JDM in the context of clinical features including skin manifestations, muscle weakness and organ damage, myositis-specific antibodies and their associated outcomes and the treatment of disease.
BACKGROUND:Juvenile dermatomyositis (JDM) is a chronic autoimmune disease characteristic by inflammation of small vessels within the skin, muscle and vital organs. But the clinical features and treatment of JDM have not been fully clarified. DATA SOURCES: Databases underwent through PubMed for articles about the clinical features, myositis-specific antibodies of JDM and its treatment, and we selected publications written in English which were relevant to the topic of this review. RESULTS: Clinical features and myositis-specific antibodies may predict the severity and prognosis of disease. Although the mortality rate has been lower with traditional treatments, such as corticosteroid, intravenous immunoglobulin, and disease-modifying anti-rheumatic drugs such as methotrexate, their usages are variable. Novel biological therapies seem to be effective for refractory JDMpatients, but more clinical trials are necessary. CONCLUSIONS:JDM is a sever disease of childhood. We need to better understand recent advances of JDM in the context of clinical features including skin manifestations, muscle weakness and organ damage, myositis-specific antibodies and their associated outcomes and the treatment of disease.
Authors: Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider Journal: Curr Rheumatol Rep Date: 2014-12 Impact factor: 4.592
Authors: Mohammad Salajegheh; Sek Won Kong; Jack L Pinkus; Ronan J Walsh; Anne Liao; Remedios Nazareno; Anthony A Amato; Bryan Krastins; Chris Morehouse; Brandon W Higgs; Bahija Jallal; Yihong Yao; David A Sarracino; Kenneth C Parker; Steven A Greenberg Journal: Ann Neurol Date: 2010-01 Impact factor: 10.422
Authors: Adam M Huber; Gulnara Mamyrova; Peter A Lachenbruch; Julia A Lee; James D Katz; Ira N Targoff; Frederick W Miller; Lisa G Rider Journal: Arthritis Care Res (Hoboken) Date: 2014-05 Impact factor: 4.794
Authors: L R Wedderburn; N J McHugh; H Chinoy; R G Cooper; F Salway; W E R Ollier; L J McCann; H Varsani; J Dunphy; J North; J E Davidson Journal: Rheumatology (Oxford) Date: 2007-11-14 Impact factor: 7.580